Literature DB >> 11003634

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation.

M Berenguer1, M Prieto, J M Rayón, J Mora, M Pastor, V Ortiz, D Carrasco, F San Juan, M D Burgueño, J Mir, J Berenguer.   

Abstract

The natural history of clinically compensated hepatitis C virus (HCV) cirrhosis after liver transplantation is unknown. This information is relevant to transplant centers to improve the management of these patients and decide the optimal timing for retransplantation. The aims of the study were (1) to describe the natural history of patients with HCV-cirrhosis transplants in a center with annual liver biopsies, and (2) to determine predictors for clinical decompensation, retransplantation, and mortality rates. A total of 49 patients with HCV-graft cirrhosis, 39 clinically compensated at histologic diagnosis of cirrhosis (post-liver transplantation cirrhosis) were included and followed up for 1 year (15 days-3.5 years). All patients tested were infected with genotype 1b. Predictive variables included histologic activity index (HAI) at post-liver transplantation cirrhosis, liver function tests, age, sex, and maintenance immunosuppression. Eighteen of 39 patients developed at least 1 episode of decompensation after a median of 7.8 months (4 days-2.6 years; 93% ascites). The cumulative probability of decompensation was 8%, 17%, and 42% at 1, 6, and 12 months, respectively. Graft and patient survival rates were 100%, 85%, and 71% and 100%, 92%, and 74% at 1, 6, and 12 months, respectively. Patient survival rates dropped significantly once decompensation developed (93%, 61%, and 41% at 1, 6, and 12 months, respectively). Variables associated with decompensation, retransplantation, and mortality rate included a high Child-Pugh score (>A), low levels of albumin at post-liver transplantation cirrhosis, and a short interval between liver transplantation and post-liver transplantation cirrhosis. The natural history of clinically compensated HCV-graft cirrhosis is shortened when compared with immunocompetent patients. If retransplantation is considered, it should be performed promptly once decompensation develops.

Entities:  

Mesh:

Year:  2000        PMID: 11003634     DOI: 10.1053/jhep.2000.17924

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  85 in total

Review 1.  [Specific infections in organ transplantation].

Authors:  M Cornberg; B Schlevogt; J Rademacher; A Schwarz; M Sandherr; G Maschmeyer
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

2.  Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.

Authors:  Angela L Rasmussen; Nicolas Tchitchek; Nathan J Susnow; Alexei L Krasnoselsky; Deborah L Diamond; Matthew M Yeh; Sean C Proll; Marcus J Korth; Kathie-Anne Walters; Sharon Lederer; Anne M Larson; Robert L Carithers; Arndt Benecke; Michael G Katze
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

Review 3.  Living donor liver transplantation to patients with hepatitis C virus cirrhosis.

Authors:  Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Authors:  Jennifer E Layden; Bamidele O Tayo; Scott J Cotler; Nina M Clark; Kristine Baraoidan; Scott L Friedman; Richard S Cooper
Journal:  Transplantation       Date:  2014-05-27       Impact factor: 4.939

5.  Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution.

Authors:  Ashwin Balagopal; Stuart C Ray; Ruben Montes De Oca; Catherine G Sutcliffe; Perumal Vivekanandan; Yvonne Higgins; Shruti H Mehta; Richard D Moore; Mark S Sulkowski; David L Thomas; Michael S Torbenson
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

Review 6.  Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Authors:  Jan Peveling-Oberhag; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  Med Microbiol Immunol       Date:  2009-11-10       Impact factor: 3.402

7.  A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

Authors:  James R Burton; Jacqueline G O'Leary; Elizabeth C Verna; Varun Saxena; Jennifer L Dodge; Richard T Stravitz; Joshua Levitsky; James F Trotter; Gregory T Everson; Robert S Brown; Norah A Terrault
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

Review 8.  [Progress in immunosuppression].

Authors:  C P Strassburg; M J Bahr; T Becker; J Klempnauer; M P Manns
Journal:  Chirurg       Date:  2008-02       Impact factor: 0.955

9.  Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.

Authors:  Audrey Coilly; Valérie Furlan; Bruno Roche; Caroline Barau; Coralie Noël; Laurence Bonhomme-Faivre; Teresa Maria Antonini; Anne-Marie Roque-Afonso; Didier Samuel; Anne-Marie Taburet; Jean-Charles Duclos-Vallée
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.